This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Markland, W.
Right arrow Articles by Kwong, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Markland, W.
Right arrow Articles by Kwong, A. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2000, p. 859-866, Vol. 44, No. 4
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Broad-Spectrum Antiviral Activity of the IMP Dehydrogenase Inhibitor VX-497: a Comparison with Ribavirin and Demonstration of Antiviral Additivity with Alpha Interferon

W. Markland,* T. J. McQuaid, J. Jain, and A. D. Kwong

Vertex Pharmaceuticals Inc., Cambridge, Massachusetts 02139-4242

Received 13 July 1999/Returned for modification 3 November 1999/Accepted 3 January 2000

The enzyme IMP dehydrogenase (IMPDH) catalyzes an essential step in the de novo biosynthesis of guanine nucleotides, namely, the conversion of IMP to XMP. The major event occurring in cells exposed to competitive IMPDH inhibitors such as ribavirin or uncompetitive inhibitors such as mycophenolic acid (MPA) is a depletion of the intracellular GTP and dGTP pools. Ribavirin is approved as an inhaled antiviral agent for treatment of respiratory syncytial virus (RSV) infection and orally, in combination with alpha interferon (IFN-alpha ), for the treatment of chronic hepatitis C virus (HCV) infection. VX-497 is a potent, reversible uncompetitive IMPDH inhibitor which is structurally unrelated to other known IMPDH inhibitors. Studies were performed to compare VX-497 and ribavirin in terms of their cytotoxicities and their efficacies against a variety of viruses. They included DNA viruses (hepatitis B virus [HBV], human cytomegalovirus [HCMV], and herpes simplex virus type 1 [HSV-1]) and RNA viruses (respiratory syncytial virus [RSV], parainfluenza-3 virus, bovine viral diarrhea virus, Venezuelan equine encephalomyelitis virus [VEEV], dengue virus, yellow fever virus, coxsackie B3 virus, encephalomyocarditis virus [EMCV], and influenza A virus). VX-497 was 17- to 186-fold more potent than ribavirin against HBV, HCMV, RSV, HSV-1, parainfluenza-3 virus, EMCV, and VEEV infections in cultured cells. The therapeutic index of VX-497 was significantly better than that of ribavirin for HBV and HCMV (14- and 39-fold, respectively). Finally, the antiviral effect of VX-497 in combination with IFN-alpha was compared to that of ribavirin with IFN-alpha in the EMCV replication system. Both VX-497 and ribavirin demonstrated additivity when coapplied with IFN-alpha , with VX-497 again being the more potent in this combination. These data are supportive of the hypothesis that VX-497, like ribavirin, is a broad-spectrum antiviral agent.

* Corresponding author. Mailing address: Vertex Pharmaceuticals Inc., 130 Waverly St., Cambridge, MA 02139-4242. Phone: (617) 577-6124. Fax: (617) 577-6210. E-mail: Markland{at}vpharm.com.

Antimicrobial Agents and Chemotherapy, April 2000, p. 859-866, Vol. 44, No. 4
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Hezode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.-P., Bourliere, M., Gharakhanian, S., Bengtsson, L., McNair, L., George, S., Kieffer, T., Kwong, A., Kauffman, R. S., Alam, J., Pawlotsky, J.-M., Zeuzem, S., the PROVE2 Study Team, (2009). Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection. NEJM 360: 1839-1850 [Abstract] [Full Text]  
  • Graci, J. D., Too, K., Smidansky, E. D., Edathil, J. P., Barr, E. W., Harki, D. A., Galarraga, J. E., Bollinger, J. M. Jr., Peterson, B. R., Loakes, D., Brown, D. M., Cameron, C. E. (2008). Lethal Mutagenesis of Picornaviruses with N-6-Modified Purine Nucleoside Analogues. Antimicrob. Agents Chemother. 52: 971-979 [Abstract] [Full Text]  
  • Noueiry, A. O., Olivo, P. D., Slomczynska, U., Zhou, Y., Buscher, B., Geiss, B., Engle, M., Roth, R. M., Chung, K. M., Samuel, M., Diamond, M. S. (2007). Identification of Novel Small-Molecule Inhibitors of West Nile Virus Infection. J. Virol. 81: 11992-12004 [Abstract] [Full Text]  
  • Chevaliez, S., Brillet, R., Lazaro, E., Hezode, C., Pawlotsky, J.-M. (2007). Analysis of Ribavirin Mutagenicity in Human Hepatitis C Virus Infection. J. Virol. 81: 7732-7741 [Abstract] [Full Text]  
  • Takhampunya, R., Ubol, S., Houng, H.-S., Cameron, C. E., Padmanabhan, R. (2006). Inhibition of dengue virus replication by mycophenolic acid and ribavirin. J. Gen. Virol. 87: 1947-1952 [Abstract] [Full Text]  
  • Gish, R. G. (2006). Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 57: 8-13 [Abstract] [Full Text]  
  • Durantel, D., Carrouee-Durantel, S., Branza-Nichita, N., Dwek, R. A., Zitzmann, N. (2004). Effects of Interferon, Ribavirin, and Iminosugar Derivatives on Cells Persistently Infected with Noncytopathic Bovine Viral Diarrhea Virus. Antimicrob. Agents Chemother. 48: 497-504 [Abstract] [Full Text]  
  • Stuyver, L. J., McBrayer, T. R., Tharnish, P. M., Hassan, A. E. A., Chu, C. K., Pankiewicz, K. W., Watanabe, K. A., Schinazi, R. F., Otto, M. J. (2003). Dynamics of Subgenomic Hepatitis C Virus Replicon RNA Levels in Huh-7 Cells after Exposure to Nucleoside Antimetabolites. J. Virol. 77: 10689-10694 [Abstract] [Full Text]  
  • Buckwold, V. E., Wei, J., Wenzel-Mathers, M., Russell, J. (2003). Synergistic In Vitro Interactions between Alpha Interferon and Ribavirin against Bovine Viral Diarrhea Virus and Yellow Fever Virus as Surrogate Models of Hepatitis C Virus Replication. Antimicrob. Agents Chemother. 47: 2293-2298 [Abstract] [Full Text]  
  • Stuyver, L. J., Whitaker, T., McBrayer, T. R., Hernandez-Santiago, B. I., Lostia, S., Tharnish, P. M., Ramesh, M., Chu, C. K., Jordan, R., Shi, J., Rachakonda, S., Watanabe, K. A., Otto, M. J., Schinazi, R. F. (2003). Ribonucleoside Analogue That Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture. Antimicrob. Agents Chemother. 47: 244-254 [Abstract] [Full Text]  
  • Lanford, R. E., Guerra, B., Lee, H., Averett, D. R., Pfeiffer, B., Chavez, D., Notvall, L., Bigger, C. (2002). Antiviral Effect and Virus-Host Interactions in Response to Alpha Interferon, Gamma Interferon, Poly(I)-Poly(C), Tumor Necrosis Factor Alpha, and Ribavirin in Hepatitis C Virus Subgenomic Replicons. J. Virol. 77: 1092-1104 [Abstract] [Full Text]  
  • Jain, J., Almquist, S. J., Heiser, A. D., Shlyakhter, D., Leon, E., Memmott, C., Moody, C. S., Nimmesgern, E., Decker, C. (2002). Characterization of Pharmacological Efficacy of VX-148, a New, Potent Immunosuppressive Inosine 5'-Monophosphate Dehydrogenase Inhibitor. J. Pharmacol. Exp. Ther. 302: 1272-1277 [Abstract] [Full Text]  
  • Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., Narita, H., Shiraki, K. (2002). In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705. Antimicrob. Agents Chemother. 46: 977-981 [Abstract] [Full Text]  
  • Lanford, R. E., Chavez, D., Guerra, B., Lau, J. Y. N., Hong, Z., Brasky, K. M., Beames, B. (2001). Ribavirin Induces Error-Prone Replication of GB Virus B in Primary Tamarin Hepatocytes. J. Virol. 75: 8074-8081 [Abstract] [Full Text]  
  • Chung, R. T., He, W., Saquib, A., Contreras, A. M., Xavier, R. J., Chawla, A., Wang, T. C., Schmidt, E. V. (2001). Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proc. Natl. Acad. Sci. USA 10.1073/pnas.171319698v1 [Abstract] [Full Text]  
  • Chung, R. T., He, W., Saquib, A., Contreras, A. M., Xavier, R. J., Chawla, A., Wang, T. C., Schmidt, E. V. (2001). Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proc. Natl. Acad. Sci. USA 98: 9847-9852 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»